DEFA14A: Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

Johnson & Johnson will acquire Intra-Cellular Therapies for $132.00 per share in cash, totaling approximately $14.6 billion, to strengthen its neuroscience leadership and add CAPLYTA to its portfolio.

Summary

• Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Intra-Cellular Therapies (ITCI) for $132.00 per share in cash, valuing the company at approximately $14.6 billion.
• The acquisition aims to strengthen J&J's neuroscience business by adding ITCI's CAPLYTA, a treatment for schizophrenia and bipolar depression, which has a potential of over $5 billion in peak year sales.
• CAPLYTA is approved for the treatment of schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder as a monotherapy and adjunctive therapy with lithium or valproate.
• The deal also includes ITI-1284, a Phase 2 compound for generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation.
• ITCI submitted a supplemental new drug application (sNDA) to the FDA for CAPLYTA as an adjunctive treatment for major depressive disorder (MDD).
• The transaction is expected to close later this year, pending regulatory approvals, ITCI stockholder approval, and other customary closing conditions.
• J&J expects to fund the acquisition through a combination of cash on hand and debt, maintaining its capital allocation priorities.
• Citi is serving as financial advisor to J&J, while Centerview Partners LLC and Jefferies are serving as financial advisors to ITCI.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the strategic acquisition, the potential of CAPLYTA, and the expansion of Johnson & Johnson's neuroscience portfolio. The deal is expected to be financially beneficial and enhance patient care.

Positives

• The acquisition strengthens Johnson & Johnson's neuroscience portfolio.
• CAPLYTA has significant sales potential, estimated at over $5 billion in peak year sales.
• The deal includes a promising clinical-stage pipeline with potential in generalized anxiety disorder and Alzheimer's disease-related psychosis and agitation.
• CAPLYTA has demonstrated statistically significant and clinically meaningful improvement in depressive symptoms in Phase 3 studies as an adjunctive treatment to antidepressants.
• The safety profile of CAPLYTA in studies was consistent with existing clinical data, with no new safety concerns identified.
• CAPLYTA can be taken at any time of day with or without food and does not require titration, allowing adult patients to start treatment at the effective dose.

Risks

• The closing of the transaction is subject to regulatory approvals and ITCI stockholder approval.
• There are risks associated with integrating the programs, products, technologies, and employees of Intra-Cellular Therapies.
• Uncertainty of clinical success and obtaining regulatory approvals for ITI-1284 and other pipeline products.
• Potential product efficacy or safety concerns resulting in product recalls or regulatory action.
• The risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act will not be obtained.
• Uncertainty as to the percentage of Intra-Cellular Therapies stockholders that will vote to approve the proposed transaction at the Intra-Cellular Therapies stockholder meeting.
• The possibility that the transaction will not be completed in the expected timeframe or at all.
• Potential adverse effects to the businesses of Johnson & Johnson or Intra-Cellular Therapies during the pendency of the transaction, such as employee departures or distraction of management from business operations.
• The risk of stockholder litigation relating to the transaction, including resulting expense or delay.
• The potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected.

Future Outlook

The transaction is expected to close later this year, subject to regulatory approvals, ITCI stockholder approval, and other customary closing conditions. Johnson & Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Management Comments

• Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson: 'Building on our nearly 70-year legacy in neuroscience, this unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitment to transforming care and advancing research in some of todays most devastating neuropsychiatric and neurodegenerative disorders.'
• Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson: 'We are excited to welcome Intra-Cellular Therapies talented people and world-class expertise to Johnson & Johnson.'
• Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies: 'Johnson & Johnson has a longstanding commitment to neuroscience, and we believe together, we can reach even more patients around the world.'

Industry Context

The acquisition reflects a growing trend in the pharmaceutical industry towards consolidation and strategic acquisitions to expand product portfolios and pipelines, particularly in high-value therapeutic areas like neuroscience. Johnson & Johnson's move to acquire Intra-Cellular Therapies aligns with this trend, as it seeks to strengthen its position in the central nervous system (CNS) disorders market.

Comparison to Industry Standards

• The acquisition price of $14.6 billion reflects a significant premium, indicating Johnson & Johnson's strong interest in Intra-Cellular Therapies' assets, particularly CAPLYTA.
• Comparable acquisitions in the pharmaceutical sector often involve similar premiums, depending on the stage of development and market potential of the acquired company's products.
• For example, Pfizer's acquisition of Biohaven Pharmaceuticals, another neuroscience-focused company, for $11.6 billion, demonstrates the high value placed on innovative therapies in this area.
• The peak year sales potential of over $5 billion for CAPLYTA is a key driver of the acquisition, positioning it as a potential blockbuster drug.
• Other companies with successful CNS drugs, such as AbbVie (Vraylar) and Otsuka (Abilify), have achieved similar or higher peak sales, indicating the potential market opportunity for CAPLYTA.

Stakeholder Impact

• Shareholders of Intra-Cellular Therapies will receive $132.00 per share in cash.
• Patients with schizophrenia, bipolar disorder, and major depressive disorder may benefit from the expanded availability and development of CAPLYTA and other therapies.
• Employees of Intra-Cellular Therapies will become part of Johnson & Johnson.
• Johnson & Johnson will strengthen its position in the neuroscience market.

Next Steps

• Intra-Cellular Therapies will file relevant materials with the SEC, including a proxy statement.
• Intra-Cellular Therapies will seek stockholder approval for the transaction.
• Johnson & Johnson and Intra-Cellular Therapies will work to obtain regulatory approvals.
• The transaction is expected to close later this year.
• Johnson & Johnson will integrate Intra-Cellular Therapies' programs, products, technologies, and employees.

Key Dates

Keywords

acquisition, intra-cellular therapies, johnson & johnson, caplyta, lumateperone, neuroscience, schizophrenia, bipolar disorder, major depressive disorder, ITI-1284, merger, pharmaceuticals